Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
Abbott (ABT) reported strong Q4 2024 results with sales of $11.0 billion, up 7.2% on a reported basis and 10.1% organic growth excluding COVID-19 testing. Full-year 2024 sales reached $42.0 billion, increasing 4.6% on a reported basis and 9.6% organic growth excluding COVID-19 testing.
The company achieved the upper end of its initial 2024 guidance ranges for both organic sales growth and adjusted earnings per share. Q4 2024 GAAP diluted EPS was $5.27, while adjusted diluted EPS was $1.34. Full-year 2024 GAAP diluted EPS was $7.64, with adjusted EPS at $4.67.
Looking ahead, Abbott projects full-year 2025 organic sales growth of 7.5% to 8.5%, with adjusted operating margin expected to be 23.5% to 24.0%. The company forecasts full-year 2025 adjusted diluted EPS of $5.05 to $5.25, representing double-digit growth at the midpoint.
Abbott Laboratories (NYSE: ABT) faces a class action lawsuit filed by the Public Health Advocacy Institute (PHAI) over allegedly misleading marketing of its 'toddler milk' products. The lawsuit targets Abbott's 'Go & Grow Toddler Drink' and 'Pure Bliss Toddler Drink,' claiming deceptive marketing practices targeting parents of children aged 12-36 months.
The complaint alleges Abbott positions these products as a natural progression from FDA-regulated infant formula, despite lacking FDA regulation and containing 22.9% and 20% added sugar respectively. The lawsuit highlights that toddler milk sales exceed $500 million annually, with advertising spending quadrupling between 2006-2015.
Medical experts, including the American Academy of Pediatrics, recommend against these products, advocating instead for healthy foods, water, and plain cow's milk for toddlers. The lawsuit seeks marketing practice changes and consumer refunds across multiple states.
Abbott (NYSE: ABT) announced it will release its fourth-quarter 2024 financial results on Wednesday, January 22, before market open. The company will host a live webcast earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. An archived version of the call will be made available later the same day.
Abbott (NYSE: ABT) has achieved a significant milestone by completing the world's first leadless left bundle branch area pacing (LBBAP) procedures using their investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system. The procedures were conducted as part of a feasibility study evaluating the system's acute safety and performance.
The innovative device, which has received FDA Breakthrough Device Designation, is designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system. This approach combines the benefits of both conduction system pacing and leadless pacing technologies, potentially offering improved physiological response compared to traditional pacing options.
The procedures were performed by Prof. Petr Neužil at Na Homolce Hospital in Prague and Dr. Vivek Y. Reddy from Mount Sinai Hospital in fall 2024.
Abbott (NYSE: ABT) has announced a 7.3% increase in its quarterly common dividend to 59 cents per share, marking its 53rd consecutive year of dividend growth. The company's quarterly dividend payout has grown more than 60% since 2020, demonstrating consistent shareholder value creation. This will be Abbott's 404th consecutive quarterly dividend since 1924. The dividend is payable on February 14, 2025, to shareholders of record as of January 15, 2025. Abbott maintains its position in the S&P 500 Dividend Aristocrats Index, which includes companies with at least 25 consecutive years of dividend increases.
Abbott and the Big Ten Conference's 'We Give Blood Drive' competition saw nearly 20,000 participants donate blood across the country, potentially saving up to 60,000 lives. The University of Nebraska-Lincoln won the competition, receiving a $1 million grant from Abbott to advance student and community health.
The initiative aimed to address one of the biggest blood shortages in a generation, particularly noting the decline in donors aged 19-24 by nearly a third in recent years. More than half of the campus blood drive donors were first-time contributors. The competition ran from September 26 through December 6 and will return next football season.
Abbott (NYSE: ABT) announced its first patient procedures using an investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating severe aortic stenosis. This system represents the initial phase toward developing a software-guided TAVI system with AI capabilities. The technology will complement Abbott's existing Navitor™ TAVI system, offering physicians additional options for patient treatment.
The balloon-expandable device works by crimping a new heart valve on a deflated balloon, which is inserted through a leg artery and guided to the heart. The balloon is then inflated to expand the valve, replacing the function of the narrowed native valve.
Tidepool has announced a new cloud-to-cloud data integration partnership with Abbott (NYSE: ABT) for continuous glucose monitoring (CGM). The integration will enable automatic data streaming from Abbott's FreeStyle Libre CGM devices to Tidepool+, a diabetes data visualization and population health platform. This partnership allows healthcare providers to initiate connections with patients using FreeStyle Libre 1, 2, and 3 devices, both in-clinic and remotely. The integration aims to streamline diabetes care workflows and provide comprehensive patient data overview through Tidepool's Population Health Dashboard.
Tidepool announces a new cloud-to-cloud data integration partnership with Abbott's FreeStyle Libre portfolio of continuous glucose monitoring (CGM) systems in the U.S. This integration will enable automatic data streaming from Abbott's CGMs to Tidepool+, a diabetes data visualization and population health platform. The collaboration aims to streamline diabetes care workflows and expand patient choice.
The integration will allow clinics and health systems using Tidepool+ to establish connections with patients using FreeStyle Libre 2 and 3 systems, either in-clinic or remotely. The platform will merge data from FreeStyle Libre sensors into its Population Health Dashboard, providing clinicians with comprehensive patient outcome assessments.
Tidepool announces a new cloud-to-cloud data integration with Abbott's FreeStyle Libre portfolio of continuous glucose monitoring (CGM) systems in the U.S. The integration will enable automatic data streaming from FreeStyle Libre 2 and 3 systems to Tidepool+, a diabetes data visualization and population health platform. This collaboration aims to streamline diabetes care workflows and provide better access to device data through interoperable solutions. Healthcare providers will be able to initiate connections with patients either in clinic or remotely, creating a comprehensive overview of patient outcomes through the Population Health Dashboard.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
